Immatics N.V Stock price
Compare with Peer Group
AI Insights on Immatics N.V
Insights
Is Immatics N.V a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.
Key metrics
Immatics N.V Stock Analysis
Analyst Opinions
16 Analysts have issued a Immatics N.V forecast:
Analyst Opinions
16 Analysts have issued a Immatics N.V forecast:
Don't miss a Thing! We will send you all news about Immatics N.V directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Immatics N.V Stock News
Company Profile
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its clinical pipelines include adoptive cell therapy (ACT) and TCR biscpecifics (TCER™). Its therapeutic approaches are ACTengine, Next Generation ACT, and TCER. The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.
| Head office | Netherlands |
| CEO | Dr. Singh |
| Employees | 650 |
| Founded | 2020 |
| Website | immatics.com |


